Iovance Biotherapeutics Quarterly Cash Flow Statement
NASDAQ: IOVAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Iovance Biotherapeutics free cash flow
In the quarter ended Jun 30, 2026, Iovance Biotherapeutics generated -$60.8 million of operating cash flow and spent $5.4 million on capital expenditures. That left free cash flow of -$66.3 million, a free-cash-flow margin of -66.7% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
Iovance Biotherapeutics cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -47.31M | -79.05M | -71.90M | -91.25M | -111.66M | -116.16M | -78.56M | -83.54M | -97.10M | -112.98M | -116.38M | -113.76M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | 3.78M | 2.82M | 3.72M | 3.19M | 3.40M | 2.57M | 3.27M | 3.00M | 3.00M | 2.98M | 2.95M | 2.90M |
| Stock-Based Compensation | 11.73M | 11.27M | 11.82M | 11.90M | 14.94M | 22.91M | 30.98M | 31.01M | 30.47M | 17.18M | 14.40M | 15.82M |
| Change in Working Capital | -35.06M | -10.86M | -4.39M | -5.96M | 11.37M | -14.38M | -39.80M | -9.36M | -36.02M | -29.76M | 14.61M | 8.70M |
| Operating Cash Flow | -60.84M | -72.07M | -52.56M | -78.70M | -67.45M | -103.69M | -73.30M | -58.97M | -98.43M | -122.28M | -83.97M | -84.08M |
| Capital Expenditures | -5.44M | -6.61M | -9.32M | -10.84M | -7.46M | -6.21M | -4.17M | -2.29M | -442.00K | -4.17M | -3.53M | -3.58M |
| Investing Cash Flow | -74.05M | 11.39M | 775.00K | 17.01M | 13.84M | 15.87M | 23.68M | -48.80M | 40.22M | -111.51M | -72.84M | -79.01M |
| Financing Cash Flow | 49.29M | 94.33M | 56.17M | 88.06M | 13.23M | 143.31M | 2.31M | 41.95M | 152.82M | 193.58M | 962.00K | 202.80M |
| Net Change in Cash | -85.73M | 33.44M | 4.96M | 25.69M | -39.64M | 56.00M | -48.49M | -64.57M | 94.49M | -40.70M | -152.83M | 37.71M |
| Free Cash Flow | -66.28M | -78.68M | -61.88M | -89.55M | -74.91M | -109.91M | -77.46M | -61.26M | -98.87M | -126.45M | -87.50M | -87.66M |
This table shows 12 quarterly periods of Iovance Biotherapeutics's cash flow statement, from Q2 2026 back to Q3 2023, across 11 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow IOVA's reporting calendar. What is a cash flow statement?